Health & Fitness / The Economic Times
India's pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which increased sales by 19% and 17% respectively, liver therapies, Liv-52 by 17%, and Udiliv 28%.
The Indian Council of Medical Research (ICMR) and the National Institute of Nutrition (NIN) have issued 17 new dietary guidelines, urging moderation in tea and coffee consumption. Citing health concerns related to caffeine, the ICMR recommends limiting daily intake to 300mg. The guidelines suggest avoiding tea or coffee an hour before and after meals to prevent iron absorption issues. Emphasizing a diverse diet, they promote increased fruit and vegetable consumption while limiting oil, sugar, an
Kotak Strategic Situations India Fund II (KSSF II) managed by Kotak Alternate Asset Managers Limited (Kotak Alt) announced investing up to Rs 400 crore in medical device manufacturer Biorad Medisys. The investment will primarily facilitate a new manufacturing plant setup, debt repayment, and increased working capital.
A relook at the survey data was necessitated by instances of repeated measles outbreaks after the COVID-19 pandemic, the report by (by Rema Nagarajan) said.
Serum Institute of India halted Covishield vaccine manufacturing and supply in December 2021 amid side effects concerns and Astrazeneca's withdrawal of Vaxzervria.
India's MedTech industry is poised for an exponential growth, set to reach USD 50 bn by 2030 from the current USD 14 billion.